Laboratory of Pharmaceutical Technology, Ghent University, Harelbekestraat 72, B-9000 Gent, Belgium.
J Appl Toxicol. 2011 Oct;31(7):640-8. doi: 10.1002/jat.1610. Epub 2010 Dec 6.
Stinging, itching and/or burning (SIB) sensations cannot be detected by animal tests or in vitro models. In the past, the Slug Mucosal Irritation (SMI) assay demonstrated a relation between an increased mucus production in slugs and an elevated incidence of SIB sensations in humans. A new 1-day SMI test procedure was developed focusing on the prediction of these short-term sensations. The objective of this study was to verify whether this new procedure is capable predicting mucosal tolerance of several marketed nasal formulations using the slug Arion lusitanicus. Irritation and tissue damage were quantified with a 5-day repeated exposure study by means of the mucus produced and proteins and enzymes released. The new protocol predicted SIB sensations by means of mucus production. The effects of six liquid nasal formulations were tested with both protocols, while five physiologic saline solutions were only tested with the new protocol to optimize it. None of the tested liquid nasal formulations resulted in tissue damage; however, exposure to the different formulations had a clear effect on the mucus production of the slugs and moderate discomfort was observed in some cases. These effects were due to the active ingredient, the presence of benzalkonium chloride as a preservative or the hyperosmolality of the formulation. For the most part results agreed with clinical data found in literature. It was concluded that the SMI assay, and the new 1-day protocol in particular, is a good tool to predict nasal clinical discomfort.
刺痛、瘙痒和/或烧灼感无法通过动物测试或体外模型检测到。过去,鼻涕虫黏膜刺激(SMI)试验表明,鼻涕虫的黏液分泌增加与人类出现较高的刺痛、瘙痒发生率之间存在关联。为了预测这些短期感觉,开发了一种新的 1 天 SMI 测试程序。本研究的目的是验证该新程序是否能够使用扁玉螺预测几种市售鼻用制剂的黏膜耐受性。通过 5 天重复暴露研究,通过产生的黏液以及释放的蛋白质和酶来量化刺激和组织损伤。新方案通过黏液产生来预测刺痛、瘙痒感觉。使用这两种方案测试了六种液体鼻用制剂的效果,而仅使用新方案测试了五种生理性盐水溶液以对其进行优化。测试的液体鼻用制剂均未导致组织损伤;然而,不同制剂的暴露对鼻涕虫的黏液产生有明显影响,在某些情况下观察到中度不适。这些影响归因于活性成分、作为防腐剂的苯扎氯铵的存在或制剂的高渗性。在大多数情况下,结果与文献中的临床数据一致。结论是,SMI 试验,特别是新的 1 天方案,是一种预测鼻临床不适的良好工具。